Navigation
banner

Genomics & Big Data Summit

2017-11-182018-03-062018-02-06
EARLY BIRD DISCOUNT! Register by Feb 06, 2018 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 speaker list is currently being formed.

Please come back and visit this page for update.

BELOW ARE THE SPEAKERS FROM 2017

PLENARY KEYNOTE SPEAKERS
Kay Eron

Kay Eron
General Manager Health & Life Sciences
Intel, Data Center Group
Kay Eron
General Manager Health & Life Sciences
Intel, Data Center Group
 
About Speaker:

Kay Eron is general manager, health & life sciences in Intel’s Data Center Group.  Kay and her team are working to transform the health and life sciences sector by deploying Intel Architecture-based analytics solutions in key areas like health IT, Genomics & personalized medicine, as well as AI in healthcare. She orchestrates the various parts of Intel - from public policy to R&D to sales to standards activities - to help scale open solutions that reduce cost, complexity, and burdens of health & life sciences customers and consumers. The solutions that Kay’s team is developing help transform healthcare to more personalized, data-driven, and quality-focused models.

Iain Fraser

Iain Fraser
Chief, Signaling Systems Unit
NIH
Iain Fraser
Chief, Signaling Systems Unit
NIH
 
About Speaker:

Iain Fraser is Chief of the Signaling Systems Unit in the Department of Systems Biology at the National Institute of Allergy and Infectious Disease at the NIH. He received his B.S. in biochemistry from Heriot-Watt University, Edinburgh, and his Ph.D. in biochemistry from Imperial College, University of London. He was a Wellcome Trust International Prize postdoctoral fellow at the Vollum Institute before joining the Alliance for Cellular Signaling (AfCS) research consortium at the California Institute of Technology. He led the AfCS Molecular Biology Laboratory at Caltech before joining NIAID. His research focuses on the mechanistic basis of cellular signaling, particularly in the context of regulation of inflammatory responses in cells of the innate immune system. His lab uses systems biology approaches to decipher how macrophage cells integrate pathogenic and host stimuli in a complex environment to ensure appropriate context-dependent cellular responses. This is vital to understanding how a breakdown in information processing through cell-surface receptors and their linked signal transduction pathways leads to human disease.

Jeffery Schloss

Jeffery Schloss
Former Director, Division of Genome Sciences, NHGRI, NIH
Independent Scientist
Jeffery Schloss
Former Director, Division of Genome Sciences, NHGRI, NIH
Independent Scientist
 
About Speaker:

Jeffery A. Schloss, Ph.D., is experienced in running programs to develop and implement genomic technologies.  He was most recently Director, Division of Genome Sciences, Extramural Research Program, National Human Genome Research Institute (NHGRI), U.S. National Institutes of Health, where he supervised the scientists who were responsible for well-known, productive programs such as NHGRI’s Genome Sequencing Program, ENCODE, 1000 Genomes, $1,000 Genome Technology program, and much of NHGRI’s informatics program, and NIH Common Fund programs including KOMP, LINCS, H3Africa, Protein Capture, and the Human Microbiome Program.  Earlier, as Program Director at NHGRI, Schloss developed and implemented the program to develop technologies to sequence human genomes at a cost of $1,000, and the Centers of Excellence in Genomic Science; in the early days of the Human Genome Project he managed grants to centers that were building human and model organism physical and genetic maps, and helped initiate the scale-up to HGP sequencing.  Schloss served on numerous trans-NIH and trans-federal-agency programs including the NIH Bioengineering Consortium and the National Nanotechnology Initiative. He was on the biology faculty at the University of Kentucky after a postdoc in the biology department at Yale University and earning the PhD degree in cell biology at Carnegie Mellon University.

PLENARY SPEAKERS
Leah Lowthorp

Leah Lowthorp
Program Manager
Center for Genetics and Society
Leah Lowthorp
Program Manager
Center for Genetics and Society
 
About Speaker:

Leah Lowthorp, Ph.D., is Program Manager and ACLS Public Fellow at the Center for Genetics and Society (CGS), a leading public interest organization that works to encourage responsible uses and effective societal governance of human genetic and assisted reproductive technologies. She brings expertise in the ethics and policy implications of emerging human biotechnologies, with a focus on human gene editing and 3-person in-vitro fertilization techniques. Prior to joining CGS, Leah taught at Harvard University and the University of Pennsylvania.

Metabolomics - Advances & Applications in Human Disease
DISTINGUISHED SPEAKERS
Daniel Braas

Daniel Braas
Scientific Director
UCLA Metabolomics Center
Daniel Braas
Scientific Director
UCLA Metabolomics Center
 
About Speaker:

Daniel Braas joined UCLA in 2005 after receiving his Ph.D. in molecular biology at the University of Münster, Germany. He first worked in Stephen Smale’s lab working on chromatin modifications and remodeling during macrophage activation. In 2009, he joined Heather R. Christofk’s lab to study the metabolism of high-grade liposarcomas. Using an in-house developed novel PET tracer, he was able to identify nucleotide salvage activity in mouse xenografts of patient-derived liposarcomas which renders them sensitive to treatment with the cytosine analog gemcitabine. In 2013, he became the Scientific Director of the newly established UCLA Metabolomics Center.

Abhishek Jha

Abhishek Jha
Co-founder
Elucidata
Abhishek Jha
Co-founder
Elucidata
 
About Speaker:

Abhishek is passionate about transforming the way data is used to drive decisions in R&D labs in biotech and pharmaceutical companies. Abhishek has been published extensively in peer-reviewed journals. Prior to co-founding Elucidata, he was an early team member at Agios Pharmaceuticals and received training at MIT, The University of Chicago and IIT Bombay.

Mike Milburn

Mike Milburn
Chief Scientific Officer
Metabolon, Inc.
Mike Milburn
Chief Scientific Officer
Metabolon, Inc.
 
About Speaker:

Dr. Milburn has served as Chief Scientific Officer since 2005 and is responsible for global metabolomics technology development, laboratory operations, informatics, and data science. Before joining Metabolon, he was Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals, where he led the preclinical/clinical development of drugs in metabolic disease and neurodegeneration. Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon and was responsible for the development of its proprietary high-throughput, scaffold-based chemical technology platform. He also held various research positions at Glaxo and GlaxoWellcome from 1991 to 2001. Dr. Milburn received his PhD in biophysical chemistry from the University of California, Berkeley and was a post-doctoral research fellow at Harvard Medical School.

Wimal Pathmasiri

Wimal Pathmasiri
Research Assistant Professor, Department of Nutrition
Nutrition Research Institute, University of North Carolina at Chapel Hill
Wimal Pathmasiri
Research Assistant Professor, Department of Nutrition
Nutrition Research Institute, University of North Carolina at Chapel Hill
 
About Speaker:

Wimal Pathmasiri, Ph.D. joined the UNC Nutrition Research Institute in March 2017 as a Research Assistant Professor in the Department of Nutrition, UNC-Chapel Hill. Dr. Pathmasiri is interested in identifying signature metabolite profiles related to disease state and the outcome of nutritional intervention to disease. He will focus on effect of diet and naturally occurring molecules in diet on gut microbiome related metabolism.

Dr. Pathmasiri earned his B.Sc. and M.Phil. from the University of Colombo, Sri Lanka, and a Licentiate of Philosophy from the Uppsala University, Sweden. He received his Ph.D. in Chemistry from Uppsala University and did postdoctoral work at the UNC Chapel and RTI International. He has been working as a Research Biochemist before joining the UNC NRI.

He is an active member of the NIH Common Fund Eastern Regional Comprehensive Metabolomics Resource Core (ERCMRC). As a metabolomics scientist, he has contributed to collaborative metabolomics research on a number of research areas: cancer, childhood obesity, early life exposure to antibiotics, environmental exposure, kidney disease, osteoarthritis, rare diseases, and toxicology.

John Ryals

John Ryals
President and CEO
Metabolon, Inc.
John Ryals
President and CEO
Metabolon, Inc.
 
About Speaker:

Dr. John Ryals co-founded Metabolon, Inc. in 2002 and serves as president and CEO. Metabolon is a pioneer and leader in the field of metabolomics and its use in precision medicine and human health. Prior to Metabolon, he was a co-founder, CEO and president of Paradigm Genetics, Inc., a publicly traded biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.

Natalie Serkova

Natalie Serkova
Professor
University of Colorado Anschutz Medical Campus
Natalie Serkova
Professor
University of Colorado Anschutz Medical Campus
 
About Speaker:

Dr. Natalie J. Serkova is Director of the University of Colorado Cancer Center/ CTSA Imaging and Metabolomics Core. She received her BS in Physics at the Fourier Institute in Grenoble (France), MS in Biophysics at the University of Kiev (Ukraine) and her MD/ PhD was in Medical Physics/ Biochemistry at the Medical School of Hannover and the University of Bremen (Germany). She continued with her postdoctoral training in the area of translational pharmacokinetics/ pharmacodynamics (PK/PD) using LC-MS, NMR spectroscopy, MRI and PET based end-points at the University of California San Francisco and Stanford. Presently, Dr. Serkova is Professor of Anesthesiology, with secondary appointments in Radiology, Radiation Oncology and Pharmacology. Dr. Natalie Serkova and her team evaluate changes in cancer biochemistry and microenvironment by applying translational metabolomics and imaging approaches for animal studies and human trials with novel anti-cancer drugs and radiation-induced inflammation. The technological platforms for her research include NMR-based quantitative metabolomics for biomarker elucidation ex vivo and their translation into non-invasive MRI and PET based metabolic imaging protocols.

Next Generation Sequencing 2017
DISTINGUISHED SPEAKERS
Tyson Clark

Tyson Clark
Director, Applications Development
Pacific Biosciences
Tyson Clark
Director, Applications Development
Pacific Biosciences
 
About Speaker:

Tyson A. Clark, Ph.D. is a Director in the R&D group at Pacific Biosciences who focuses on development of new applications that utilize PacBio’s long read sequencing technologies. Dr. Clark received his doctorate degree in Molecular Biology from the University of California, Santa Cruz in 2002. He was a pioneer in the use of microarrays to study alternative splicing at a genome-wide scale. After working in the gene expression space at Affymetrix, Dr. Clark joined Pacific Biosciences in 2009. He has worked on a broad range of applications of SMRT® Sequencing, including direct detection of modified DNA bases, but his current focus is on the use of long reads for targeted sequencing and to sequence full-length cDNA transcripts.

Joshua Edel

Joshua Edel
Professor, Chemistry
Imperial College London
Joshua Edel
Professor, Chemistry
Imperial College London
 
About Speaker:

Prof. Joshua Edel received his PhD on the development of single molecule detection within microfluidic systems at Imperial College London in 2003. He then performed postdoctoral research in nanobiotechnology at Cornell University within the School of Applied and Engineering Physics. In 2005 he was awarded a research fellowship in single molecule biophysics at the Rowland Institute at Harvard University. In July 2006 he joined Imperial College London within the Department of Chemistry and Institute of Biomedical Engineering as a lecturer. Joshua is currently a Professor in the Department of Chemistry and in 2011 he was awarded a prestigious ERC Starting Grant on “Nanoporous Membranes for High Throughput Rare Event Bioanalysis” and in 2016 he was awarded an ERC Consolidator Grant related to the development of selective single molecule biosensors.

Richard McCombie

Richard McCombie
Professor & Director, The Stanley Institute for Cognitive Genomics
Cold Spring Harbor Laboratory
Richard McCombie
Professor & Director, The Stanley Institute for Cognitive Genomics
Cold Spring Harbor Laboratory
 
About Speaker:
John Oliver

John Oliver
Chief Technology Officer
Nabsys 2.0
John Oliver
Chief Technology Officer
Nabsys 2.0
 
About Speaker:

John Oliver, Ph.D. is the Chief Technology Officer at Nabsys 2.0 LLC where he is responsible for overseeing all aspects of the scientific development of the company’s DNA mapping platform. Dr. Oliver brings over 25 years of research expertise to Nabsys. His diverse experience includes synthetic organic chemistry, biochemistry, molecular biology, surface chemistry, and microarray technology. Dr. Oliver previously served as Chief Scientific Officer at GeneSpectrum Inc. an array-based sequencing company that he co-founded in 2000 with colleagues from Brown University. Prior to founding GeneSpectrum, Dr. Oliver was an assistant professor of Chemistry at Brown University. His research group focused on developing methods of performing non-natural amino acid mutagenesis, identifying novel catalysis mechanisms, and investigating biosynthetic pathways for terpene natural products. Dr. Oliver received a MS and a PhD in Chemistry from Northwestern University in Evanston, IL. He is a graduate of Harvey Mudd College where he received a Bachelor of Science in Chemistry.

Michael Phelan

Michael Phelan
Senior Scientist, R&D
Fluidigm Corporation
Michael Phelan
Senior Scientist, R&D
Fluidigm Corporation
 
About Speaker:

Michael L. Phelan, PhD, is Senior Research Scientist and Project Leader at Fluidigm, where his focus is on single cell and low input NGS library preparation, primarily mRNA-Seq. Dr. Phelan has played an important role in advancing the performance of the C1 HT IFC, for the capture, imaging and characterization of 800 single cells. He received his PhD from McGill University studying Transcriptional Regulation of Embryonic Patterning and conducted his Postdoctoral Research at Massachusetts General Hospital/Harvard Medical School researching the role of Chromatin Remodeling Complexes in gene regulation.

Flora Tassone

Flora Tassone
Professor, Biochemistry and Molecular Medicine; M.I.N.D. Institute Investigator
University of California, Davis, School of Medicine
Flora Tassone
Professor, Biochemistry and Molecular Medicine; M.I.N.D. Institute Investigator
University of California, Davis, School of Medicine
 
About Speaker:

She received a PhD from the Catholic University of Rome, Italy, for her studies on Down Syndrome. During the postdoctoral fellowship, first at the Eleanor Roosevelt Institute in Denver, and then at University of Colorado Health Science Center she continued to work on the identification of genes involved in Down Syndrome and started to focus her attention on the molecular basis leading to Fragile X syndrome and autism spectrum disorders.

In 2001 she moved to the University of California, Davis and focused her research on neurodevelopmental disorders including Fragile X syndrome and associated disorders, autism spectrum disorders and 22q deletion syndrome.

Her expertise is in transcriptional and translational regulation of the fragile X (FMR1) gene. Dr. Tassone has carried out a significant work on the molecular characterization of premutation alleles and the association with a number of clinical features observed in carriers. Dr. Tassone has made a number of important observations related to the mechanism of gene expression of the FMR1 gene, especially regarding the effects of premutation alleles in individuals that the scientific community thought to be clinically unaffected. Specifically, she investigated the clinical manifestations, protein and FMR1 mRNA expression in individuals with fragile X syndrome and made the important discovery of gene dysregulation (increased mRNA activity) among premutation carriers. This discovery provided the molecular basis for the forms of clinical involvement among carriers, including fragile X-associated tremor/ataxia syndrome (FXTAS), which was described in 2001 by her team. Since then, she has been investigating the molecular mechanisms involved in the FMR1- associated disorders.

She has conducted a pilot study on Newborn Screening in Fragile X syndrome, funded by NICHD, the first of its kind in United States, which has generated prevalence data on expanded alleles, using a PCR-based methodology that she developed in her Lab.

With the advent of clinical trials she has been involved in the development of molecular biomarkers predictive of drug efficacy and monitoring disease severity.

Her research is also focused on other neurodevelopmental disorders including autism spectrum disorders and 22q deletion syndrome, since a significant number of children with fragile X syndrome and 22q deletion also have autism. Specifically, she is involved in the identification of susceptibility genes that play a role in the pathogenesis of autism.

Dr. Tassone has extensive experience in medical genetics and clinical analysis. She has been granted multiple awards, fellowships and training opportunities, as well as research awards from NIH and several funding agencies.

John Thompson

John Thompson
Chief Technology Officer
Claritas Genomics
John Thompson
Chief Technology Officer
Claritas Genomics
 
About Speaker:

John Thompson’s career has spanned pharmaceutical, next-gen sequencing, and genetic testing industries. As Chief Technology Officer at Claritas Genomics, he is responsible for improving genetic assays for diagnosing pediatric disease and developing the next generation of assays. At Nabsys, he advanced mapping and sequencing of very long DNAs using fully solid-state nanodetectors. Prior to Nabsys, he was Senior Director of Genomic Research at Helicos BioSciences for four years, helping to develop the first commercial single-molecule, next-generation sequencing platform and apply it to a range of DNA and RNA sequencing applications. Before that, his contributions at Pfizer used molecular biology and genetic approaches to identify novel therapeutic targets, to establish the genetic basis of drug response, and to characterize the genetics of drug-induced adverse events.

Meni Wanunu

Meni Wanunu
Professor, Department of Physics
Northeastern University
Meni Wanunu
Professor, Department of Physics
Northeastern University
 
About Speaker:

Professor of biophysics, interest in single-molecule DNA/RNA sequencing, nanopores, optics, waveguides.

Big Data Bioinformatics 2017
DISTINGUISHED SPEAKERS
Alon Arad

Alon Arad
Computer Vision Lead
ReadCoor
Alon Arad
Computer Vision Lead
ReadCoor
 
About Speaker:

Dr Alon Arad is a computer vision lead at readcoor. Previously held a position as a visiting scientists at MIT in the mathematics department and was also a team lead of image processing at Shell Oil.

Hannah Carter

Hannah Carter
Assistant Professor of Medicine, Division of Medical Genetics
University of California, San Diego
Hannah Carter
Assistant Professor of Medicine, Division of Medical Genetics
University of California, San Diego
 
About Speaker:

The Carter Lab uses computation to study the impact of cancer-associated DNA mutations on intracellular biological processes and cellular behaviors. Current projects focus on identifying variation that contributes to cancer predisposition or that can be exploited for cancer therapy. Dr. Carter is a Siebel Scholar and a recipient of a 2013 NIH Director's Early Independence Award.

Dexter Hadley

Dexter Hadley
Assistant Professor of Pediatrics
Institute for Computational Health Sciences, University of California, San Francisco
Dexter Hadley
Assistant Professor of Pediatrics
Institute for Computational Health Sciences, University of California, San Francisco
 
About Speaker:

Dr. Hadley's expertise is in translating big data into precision medicine and digital health. His background is in genomics and computational biology and he has training in clinical pathology. His research generates, annotates, and ultimately reasons over large multi-modal data stores to identify novel biomarkers and potential therapeutics for disease. His early work resulted in a successful precision medicine clinical trial for ADHD (ClinicalTrials.gov Identifier: NCT02286817) for a first-in-class, non-stimulant neuromodulator to be targeted across the neuropsychiatric disease spectrum. More recently, his laboratory was funded by the NIH Big Data to Knowledge initiative to develop the stargeo.org online portal to crowd-source annotations of open genomics big data that allows users to discover the functional genes and biological pathways that are defective in disease. In addition to his genomics work, he develops state-of-the-art data driven models of clinical intelligence that drive clinical applications to more precisely screen, diagnose, and manage disease.

Brian Laffin

Brian Laffin
Associate Director Translational Diagnostics
Definiens
Brian Laffin
Associate Director Translational Diagnostics
Definiens
 
About Speaker:

Brian Laffin, PhD, is Associate Director of Translational Diagnostics at Definiens, where he provides translational science and image analysis support for client translational and clinical programs as well as internal initiatives, focused on immune oncology, antibody-drug conjugates, and IHC assay development. Brian received his PhD in Toxicology from Texas A&M University, and conducted post-doctoral research at UT MD Anderson Cancer Center and UC Denver studying androgen independent prostate cancer and VEGF signaling, respectively. 

Toby Richardson

Toby Richardson
Vice President, Bioinformatics
Synthetic Genomics
Toby Richardson
Vice President, Bioinformatics
Synthetic Genomics
 
About Speaker:

Dr Richardson joined SGI in August of 2006 and has served as VP of Informatics since 2008. He was responsible for initially setting up the informatics and software engineering departments and has led the development and implementation of SGIs proprietary genomics software platform Archetype®. Toby is also responsible for ensuring that SGI is on the cutting edge of the latest NGS platforms and computational biology tools and the implementation of these tools across the R&D groups at SGI. Prior to joining SGI, Dr Richardson spent ten years at Diversa Corporation, where he successfully ran and managed both an enzymology and informatics group and his team developed some of the first tools to annotate, store, and mine metagenomic information from environmental samples. Prior to joining the industrial biotechnology sector, Dr Richardson during his Ph.D and postdoctoral research spent 10 years studying cytochrome P450.

Anurag Sethi

Anurag Sethi
Bioinformatics Scientist
Seven Bridges
Anurag Sethi
Bioinformatics Scientist
Seven Bridges
 
About Speaker:

Anurag Sethi is a Bioinformatics Scientist at Seven Bridges Genomics, a provider of cloud-based platforms for conducting bioinformatic analyses. Anurag is actively involved in collaborative projects on the Cancer Genomics Cloud as part of his current role. Previously, he was working as a research scientist at Yale University, where he performed research on functional genomics and was a valuable member of the ENCODE consortium. He graduated from the University of Illinois at Urbana-Champaign with a PhD in Chemistry where his thesis was based on developing new tools for structural bioinformatics and network analyses of biophysical simulations.

Alex Sherman

Alex Sherman
Director, Strategic Development & Systems Neurological CRI; Principal Associate in Neurology
Massachusetts General Hospital; Harvard Medical School
Alex Sherman
Director, Strategic Development & Systems Neurological CRI; Principal Associate in Neurology
Massachusetts General Hospital; Harvard Medical School
 
About Speaker:

Alex's interests and passion are in developing collaborations in clinical research and building disease-specific research networks and consortia to achieve “Big Data” in rare diseases. Other areas of his research are understanding the benefits of patient-centric research and incentives for research collaborations and data sharing. He is a frequent speaker at academic and industry conferences and has many publications on the topics of collaboration in clinical research, data and biospecimen sharing and technology utilization for these purposes. As the Director of Strategic Development & Systems at the Neurological Clinical Research Institute at Massachusetts General Hospital, Alex is responsible for the successful design, development and deployment of software platforms for numerous clinical trials and biomarker studies in neurological diseases. Alex conceived and was instrumental in design, development and adoption by the international research community of NeuroBANK™ platform, an accelerated clinical research environment, currently utilized by numerous researchers and institutions worldwide. His team was responsible for conception, design and implementation of PRO-ACT - the largest clinical dataset from clinical trials data in ALS and the first such attempt in a rare diseases space. This platform was selected as the Best Practices winner by the Bio-IT World Congress in 2013 and by Clinical Informatics News in 2016. Alex is a Board Member of the ALS Research Group (ALSRG) and a founding Board Member of ALD Connect research consortium. Mr. Sherman holds Masters of Science degree in Nuclear Engineering and graduated from a doctorate program in Nuclear Engineering. He is a Principal Associate in Neurology at Harvard Medical School.

Glenn Tesler

Glenn Tesler
Professor, Department of Mathematics
University of California, San Diego
Glenn Tesler
Professor, Department of Mathematics
University of California, San Diego
 
About Speaker:

Glenn Tesler is a Professor in the Department of Mathematics at the University of California, San Diego, a core faculty member in the interdisciplinary graduate and undergraduate programs in Bioinformatics, and an Affiliate Faculty member of Computer Science and Engineering. He received his Ph.D. in Mathematics from the Massachusetts Institute of Technology, where his research was focused in the area of Algebraic Combinatorics. He subsequently gained an interest in Bioinformatics through problems that could be modeled using combinatorial methods. In Bioinformatics, he has done research in computational and algorithmic aspects of comparative genomics, genome rearrangements, sequence assembly, and genome-wide association studies.

CRISPR & Genome Engineering 2017
DISTINGUISHED SPEAKERS
Daniel Anderson

Daniel Anderson
Assoc. Prof., Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology
Massachusetts Institute of Technology
Daniel Anderson
Assoc. Prof., Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology
Massachusetts Institute of Technology
 
About Speaker:

Professor Daniel G. Anderson is a leading researcher in the field of nanotherapeutics and biomaterials. He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in Prof. Anderson’s laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances and products in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy and material science. Prof. Anderson received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis. His work has resulted in the publication of over 300 papers, patents and patent applications. These patents were the basis for the foundation of a number of companies in the pharmaceutical, biotechnology, and consumer products space, and have led to a number of products that have been commercialized or are in clinical development.

Joe Bondy-Denomy

Joe Bondy-Denomy
Faculty Fellow, Department of Microbiology & Immunology
UCSF
Joe Bondy-Denomy
Faculty Fellow, Department of Microbiology & Immunology
UCSF
 
About Speaker:

I have been an independent fellow at UCSF for two years, and transitioning into a faculty position at UCSF in November. I have been in the Department of Microbiology & Immunology for both positions. Prior to this I was a graduate student at the University of Toronto in Alan Davidson's lab.

Jonathan Chesnut

Jonathan Chesnut
Sr. Director, Synthetic Biology R&D
Thermo Fisher Scientific
Jonathan Chesnut
Sr. Director, Synthetic Biology R&D
Thermo Fisher Scientific
 
About Speaker:

Jon Chesnut received a PhD in Cell and Molecular Biology from UC Davis (1994), and did postdoctoral studies at the University of Colorado in recombinant antibody technology development (1994-95). Prior to graduate school, he was employed at the Salk Institute (1983-84) and Hybritech Inc. in La Jolla, CA (1984-88). After his post doctoral research at Colorado he joined Invitrogen as a research scientist (1995). Since then he has led the development of various prokaryotic and mammalian cell cloning and expression systems. He has led groups focused on development of TOPO and Gateway cloning as well as the human embryonic cell engineering technologies. He now leads the Synthetic Biology Research and Development Team in the Life Sciences Solutions Group of Thermo Fisher Scientific in Carlsbad, CA. His group is focused on developing tools for the entire Synthetic Biology and Cell Engineering workflow, specifically Bioinformatics, Genome Editing, and Cellular Analytics.

CB Gurumurthy

CB Gurumurthy
Associate Professor, Developmental Neuroscience
University of Nebraska Medical Center
CB Gurumurthy
Associate Professor, Developmental Neuroscience
University of Nebraska Medical Center
 
About Speaker:

CB Gurumurthy is an Associate Professor of Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation, and he serves as the Director of UNMC Mouse Genome Engineering Core Facility at the University of Nebraska Medical Center. He received his BVSC (DVM) from Bangalore Veterinary College, India and MVSC & PHD in Veterinary Virology from Indian Veterinary Research Institute with a Gold Medal distinction in MVSC. Prior to his current position, he served as a Molecular Biology Scientist, Drug Discovery Research at Dr. Reddy’s Laboratories, and then he moved to Northwestern University, Chicago for a Post-Doctoral work in Cancer Biology and Mouse Molecular Genetics. He also received his Executive MBA from University of Nebraska at Omaha. His research interests are improving and development of novel genome engineering technologies.

Eric Ostertag

Eric Ostertag
Chief Executive Officer
Poseida Therapeutics
Eric Ostertag
Chief Executive Officer
Poseida Therapeutics
 
About Speaker:

Dr. Ostertag is the founder and CEO of Poseida Therapeutics, Inc. (Poseida), a private biotechnology company headquartered in San Diego, CA. Poseida is a therapeutics-focused biotechnology company using best-in-class gene editing technologies to develop novel, life-saving therapies, including gene therapy for orphan liver diseases and immuno-oncology therapeutics for several types of cancer. In addition to Poseida, Dr. Ostertag has founded and managed several other successful biotechnology companies, for which he has raised over $60M. He has received numerous scientific, clinical and business awards, including awards from the American Society of Human Genetics, the American Society for Apheresis, American Association of Blood Banks, the Howard Hughes Medical Institute and Ernst & Young.

Edward Rebar

Edward Rebar
Vice President, Technology
Sangamo Therapeutics
Edward Rebar
Vice President, Technology
Sangamo Therapeutics
 
About Speaker:

Edward Rebar, Ph.D. is Vice President of Technology at Sangamo BioSciences, where he directs the design and characterization of zinc finger nucleases for therapeutic applications. Prior to this role Ed held several other leadership positions at the company, including Senior Director, Technology, in which he led the development of Sangamo’s zinc finger protein design platform and co-managed the company’s partnership with Sigma Aldrich. Ed has coauthored 59 publications relating to the development of customized DNA binding proteins and nucleases for genome editing, as well as numerous patents. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley. Ed earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.

Garrett Rettig

Garrett Rettig
Sr. Staff Scientist, Molecular Genetics
Integrated DNA Technologies
Garrett Rettig
Sr. Staff Scientist, Molecular Genetics
Integrated DNA Technologies
 
About Speaker:

Garrett has been at IDT since 2008. During that time, he has been primarily involved in high-throughput in vitro screening of siRNAs, as well as other oligonucleotide-based technologies in cell biology applications. Most recently, he has been focused on developing CRISPR technologies at IDT and applying Next Generation Sequencing strategies to detecting on-target and off-target editing events.

Ron Weiss

Ron Weiss
Director, MIT Synthetic Biology Center; Professor, Biological Engineering
Massachusetts Institute of Technology
Ron Weiss
Director, MIT Synthetic Biology Center; Professor, Biological Engineering
Massachusetts Institute of Technology
 
About Speaker:

Ron Weiss is Professor in the Department of Biological Engineering and in the Department of Electrical Engineering and Computer Science at the Massachusetts Institute of Technology, and is the Director of the Synthetic Biology Center at MIT.  He is also the Principal Investigator of the MIT Center for Integrative Synthetic Biology established and funded in September of 2013 as part of the NIH-NIGMS national centers for systems biology (cisb.mit.edu).  He received his PhD from MIT in 2001 and held a faculty appointment at Princeton University between 2001 and 2009.  His research focuses primarily on synthetic biology, where he programs cell behavior by constructing and modeling biochemical and cellular computing systems.  A major thrust of his work is the synthesis of gene networks that are engineered to perform in vivo analog and digital logic computation.  He is also interested in programming cell aggregates to perform coordinated tasks using cell-cell communication with chemical diffusion mechanisms such as quorum sensing.  He has constructed and tested several novel in vivo biochemical logic circuits and intercellular communication systems.  Weiss is engaged in both hands-on experimental work and in implementing software infrastructures for simulation and design work.

 For his work in synthetic biology, Weiss has received MIT's Technology Review Magazine's TR100 Award ("top 100 young innovators", 2003), was selected as a speaker for the National Academy of Engineering's Frontiers of Engineering Symposium (2003), and received the E. Lawrence Keyes, Jr. / Emerson Electric Company Faculty Advancement Award at Princeton University (2003).  In addition, his research in Synthetic Biology was named by MIT's Technology Review Magazine as one of "10 emerging technologies that will change your world" (2004).  He was chosen as a finalist for the World Technology Network’s Biotechnology Award (2004), and was selected as a speaker for the National Academy of Sciences Frontiers of Science Symposium (2005).  Over the last few years, Weiss has had several major publications in journals such as Nature, Nature Biotechnology, Science and PNAS.